GlobalMinds: a global genetic and health-record database to improve personalized care for people with serious mental illness and dementia
Developing an Internationally-diverse, Linked Genomic and Longitudinal Phenotypic Research Dataset to Accelerate Precision Psychiatry for Patients With Serious Mental Illness
This project will collect whole-genome data and linked health records from 50,000 adults with major mental illnesses or dementia to see if combining genetic and clinical information can help personalize diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50000 (estimated) |
| Ages | 18 Years to 110 Years |
| Sex | All |
| Sponsor | Akrivia Health Industry-sponsored |
| Locations | 1 site (Oxford, Oxford) |
| Trial ID | NCT06641726 on ClinicalTrials.gov |
What this trial studies
GlobalMinds will enroll 50,000 adults with bipolar disorder, schizophrenia, major depressive disorder, or dementia and collect biological samples alongside their electronic health records. The program will perform whole genome sequencing and additional biomarker analyses, then link those data to longitudinal clinical information available through the Akrivia Health platform. Investigators will apply advanced analytic approaches to explore new ways of grouping symptoms, predicting outcomes, and identifying biologically informed subtypes. The resource will be made available to qualified researchers to accelerate development of targeted diagnostics and treatments.
Who should consider this trial
Good fit: Adults (18+) with an accessible electronic health record who have been diagnosed with or referred/treated for major depressive disorder, bipolar disorder, schizophrenia, or dementia, who can consent, communicate in English, and (for dementia participants) complete a validated cognitive assessment.
Not a fit: People without capacity to give consent, those lacking an accessible electronic health record, non-English speakers who cannot complete study procedures, and individuals under 18 are not eligible and therefore will not benefit from participation.
Why it matters
Potential benefit: If successful, this resource could lead to more accurate diagnoses, better prediction of illness course, and more personalized treatment options for people with serious mental illness and dementia.
How similar studies have performed: Large genomic and EHR-linked efforts (for example UK Biobank and work from the Psychiatric Genomics Consortium) have identified genetic associations and shown promise, but translation into routine personalized psychiatric care remains limited, so this program builds on promising but still-emerging evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- All participants must have an electronic health record in a primary or secondary care service. Mental Health cohort(s) • Have received a diagnosis and/or treatment/referral for mental illness for MDD, BD, Schizophrenia. • Having an available electronic health record • Current age 18+ (no upper age limit) • Can speak English Dementia cohort • Participants aged 18+ (no upper age limit) • Currently alive and are, or have been, old age psychiatry patients • Received relevant diagnosis or referral: EITHER • Clinical diagnosis of dementia, mild cognitive impairment (MCI) or subjective cognitive impairment (SCI) OR • Memory clinic referral • Must be willing and able to complete a validated cognitive assessment (MoCA or SLUMS). All dementia patients will undergo the extended biomarker analysis. Exclusion Criteria: \- Mental Health cohort(s) • Patients without capacity to provide consent. Dementia cohort • Inability to understand spoken and/or written spoken English • Individuals with intellectual disability. • Patients with dementia in Creutzfeldt-Jakob disease (CJD), Huntington's, HIV dementia, alcohol-related dementia, intellectual disability, traumatic brain injury at any time. • Patients diagnosed with depression (only an exclusion criterion for MCI/SCI patients), psychosis, bipolar disorder prior in the pre-index period - to be checked at screening.
Where this trial is running
Oxford, Oxford
- GlobalMinds central study team — Oxford, Oxford, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Prof. James Walters — Cardiff University
- Study coordinator: Samantha Yuille, PhD
- Email: samantha.yuille@akriviahealth.com
- Phone: (44) 7827018555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.